FDA's 15-Year Long-Term Follow-Up Regulation and the Introduction of the 'LTFU-01' Trial

Seattle Children's Therapeutics (SCTx) has officially registered the 'LTFU-01' observational study (NCT07424157) to monitor the long-term safety of its Chimeric Antigen Receptor T-cell (CAR-T) and gene therapy products. This trial is a large-scale safety monitoring project that tracks pediatric and adolescent patients who have received gene therapy for up to 15 years after their last dose. It focuses on early screening for potential risks, such as delayed adverse effects due to genomic modifications or secondary malignancies that may occur unexpectedly. This is a proactive measure to meet the stringent post-market surveillance guidelines for gene therapies set by the U.S. Food and Drug Administration (FDA), and it is an essential step toward obtaining future marketing approval (Biologics License Application, BLA).

Safety Verification of Key Next-Generation Pipelines, Including SC-DARIC33

One of the key drugs included in this long-term follow-up is 'SC-DARIC33,' which is in Phase 1 clinical trials (PLAT-08) targeting patients with relapsed or refractory pediatric acute myeloid leukemia (AML). 'SC-DARIC33' is designed with a Dimerizing Agent Regulated Immunoreceptor Complex (DARIC) platform, ensuring that the infused T cells are regulated and activated only by the administration of rapamycin. In addition, the 'BrainChild' series, a CAR-T pipeline targeting brain tumors that is directly administered into the cerebrospinal fluid, and the 'STRIvE' series, for solid tumors, will also be included in the monitoring. The study will monitor the long-term persistence of therapeutic cells in the body and delayed toxicity in the body's microenvironment to demonstrate the inherent safety of the technology.

Addressing the Needs and Unmet Demands in the Pediatric Cancer Market

As of 2025, the pediatric brain tumor and central nervous system (CNS) tumor market is estimated at approximately $2.8 billion (USD) and is expected to grow to approximately $5.1 billion (USD) by 2034. Because pediatric patients have a long life expectancy after treatment, managing toxicity and demonstrating long-term safety during the growth process are critical factors in gaining the trust of global regulatory agencies and clinicians. The current standard of care, chemotherapy and radiation therapy, can cause severe and permanent brain damage, so there is a high unmet need for next-generation CAR-T therapies with controlled side effects. Therefore, securing 15 years of follow-up data is expected to be a key foundation for improving long-term survival rates and reducing the risk of side effects, thereby increasing the commercial value of the pipeline.

Commercialization Acceleration Through Partnerships and Spin-Outs

To overcome the limitations of a research institution, SCTx is closely collaborating with listed biotech companies such as '2seventy bio (TSVT)' and spun out 'BrainChild Bio' in late 2023 to focus on the commercialization of CAR-T therapies for pediatric brain tumors. The 'LTFU-01' trial is scheduled to begin on March 31, 2026, and be completed on March 31, 2041. Given the long study period, establishing partnerships and securing stable operating funds are essential, and Seattle Children's Hospital's independent equity investment model is playing a vital role. This initiative, which systematically establishes a protocol for long-term safety of Phase 1 candidates in a non-profit R&D ecosystem, will set a precedent for mitigating gene therapy development risks across the industry.